Priority Access Is Earned on the Clinical Case, Not the Application.
Breakthrough Device designation strategy — interactive review, senior FDA engagement, and priority handling for devices that offer more effective treatment of serious conditions.
Eligibility Is Narrow, Written Down, and Frequently Misread.
Both criteria must be met. The first is a single test; the second offers four alternatives, of which you need exactly one.
More Effective Treatment or Diagnosis of a Serious Condition
The device must provide for more effective treatment or diagnosis of life-threatening or irreversibly debilitating human disease or conditions. “Serious” is doing real work in that sentence — and so is “more effective,” which is a comparative claim you must be able to support.
And It Must Also Be One of These
The second criterion is satisfied by a single qualifying characteristic. Most requests that fail, fail here — not because the device lacks merit, but because the case for the specific characteristic was never made.
Represents breakthrough technology
No approved or cleared alternatives exist
Offers significant advantages over existing approved or cleared alternatives
Availability is in the best interest of patients
It Buys Access to the Agency. It Does Not Lower the Bar.
Designation is frequently oversold internally. These are the corrections we find ourselves making.
What You Get
- Interactive and timely communication with the review team as the science evolves
- Senior management engagement at FDA — decisions escalated rather than stalled
- Priority review of your submissions
- Data development plans agreed with the agency — what is premarket, what shifts post-market
- Sprint discussions that close a specific question in weeks rather than a cycle
What You Don’t
- A lower authorization standard. The 510(k), De Novo, or PMA bar is unchanged
- A guaranteed approval — or any promise about the outcome
- Reimbursement. Payers make their own call on their own evidence
- A marketing claim. Designation is not clearance, and saying so is a promotional problem
- Value without effort — unused access is the most common way the program disappoints
Access, Used Well, Is Worth More Than Any Procedural Concession.
For a novel device facing genuine scientific uncertainty, the ability to work a data development plan through with the review team — as the evidence emerges, not after it hardens — is the whole value of the program. A designated device still has to clear its 510(k), De Novo, or PMA bar.
Designation is a relationship, not a discount — and the teams that get value from it are the ones who arrive at each interaction with real questions and real data, not status updates.
Sprint discussions pay off only for teams who bring the agency a question worth its senior reviewers’ time.
Six Disciplines That Win and Use a Designation.
Getting designated is the easy half. Converting access into a shorter path is the work.
Eligibility Analysis
The honest read on both criteria — and on which of the four alternatives your evidence can actually carry — before the request consumes a quarter.
Designation Request Build
A request that argues the comparative claim with data rather than adjectives: the device, the condition, the alternative, and why the case holds.
Sprint Discussion Management
The focused interactions the program enables, run as decision meetings — each one closing a specific question that would otherwise surface in review.
Data Development Plans
The evidence roadmap agreed with FDA: what gets generated premarket, what shifts to post-market, and what the balance rests on.
Priority Review Execution
Priority handling only helps if your submission is ready to be handled — the file built to move at the speed the designation offers.
Designation & Reimbursement Reality
What designation means — and doesn’t — for payers, so the commercial team plans against the actual coverage landscape.
Six Failure Modes We Are Brought In to Prevent.
The most common one is winning the designation and doing nothing differently.
“Serious condition” asserted
A request that assumes the indication qualifies rather than establishing it — declined on the first criterion, publicly, inside your own company.
Four alternatives, none argued
A request gesturing at all of criterion two and committing to none — leaving the reviewer to pick the weakest reading.
“Significant advantage” without a comparison
The comparative claim made against a strawman — or against no named alternative at all.
Sprints spent on updates
Priority access to senior reviewers used for status meetings — the single largest waste of the program’s value.
Designation announced as approval
Press releases and investor decks that blur designation into clearance — a promotional exposure with a designated product’s visibility.
Reimbursement assumed to follow
A commercial plan built on the belief that designation moves payers — discovered after launch, at the worst possible moment.
Designation Strategy for Devices That Genuinely Qualify.
Our leads have argued eligibility, run sprint discussions, and turned data development plans into shorter, cleaner reviews.
“Designation gets you into the room faster. What you bring into the room is still the whole game.”
The discipline we bring to expedited device programs.
Think You Qualify? Test the Case Before You Spend a Quarter on the Request.
A senior device lead can read your eligibility against both criteria in one working session — and tell you plainly if the answer is no.
Senior-led. Embedded in your team. No junior hand-offs.